fda - Search News

News

FDA suspends Valneva's chikungunya vaccine license in U.S.

FDA suspends Valneva's chikungunya vaccine license in the U.S.

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with immediate effect, the French drugmaker said on Monday.

Fierce Pharma · 1h

FDA does a 180, suspending use of Valneva's chikungunya vaccine

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States. | Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq,

STAT · 4h

FDA pulls biologics license for chikungunya vaccine

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and efficacy study for the antidepressant Paxil, and more.

Blue Bell Ice Cream, FDA

Yahoo · 2d

FDA Announces Recall on Over 20,000 Cans of 7Up—Here’s What to Know

FDA recalls 7Up Zero Sugar Tropical Soda for being mislabeled full-sugar soda. The affected cans were sold in 12-packs in Alabama, Florida and Georgia. This was just classified as a Class II recall, meaning it may cause reversible health effects.

EatingWell on MSN · 1m

FDA Announces Recall on Blue Bell Ice Cream—Here’s What to Know

Blue Bell recalls Moo-llennium Crunch ice cream mislabeled as Cookie Dough in 16 states. Products may contain undeclared almonds, walnuts and pecans, posing serious allergy risks. Check for lot code “061027524” and return to your place of purchase for a refund.

CBS News · 39m

Blue Bell ice cream containing nuts recalled over allergy risk posed by mislabeling

Blue Bell ice cream is recalling cartons of nut-filled ice cream which were mislabeled as Chocolate Chip Cookie Dough.

Verywell Health on MSN20m

Wegovy Is Now the Second FDA-Approved Treatment for MASH Fibrosis

Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...

Fierce Pharma2h

FDA rolls out daily updates to adverse event dashboard, plans to further 'streamline' system

As the HHS and FDA leadership continues to look for ways to boost transparency and reshape the United States' healthcare ...

Fierce Biotech2h

After month-long delay, Coya Therapeutics receives FDA go-ahead for ph. 2 ALS trial

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

1don MSN

FDA clears Papzimeos to treat adult respiratory papillomatosis

The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...

4don MSN

Noodle Recall Update as FDA Issues Risk Warning

The FDA classifies this recall as Class II, which the agency describes as a situation "in which use of or exposure to a ...

Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025

SCA slowdown, with FDA review set for Q4 2025 and no advisory meeting required. Find out why BHVN stock is a strong buy.

The American Journal of Managed Care1h

FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C

The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...

Money Talks News on MSN1h

Your Red Candy's Days Are Numbered: FDA Phases Out Controversial Dye

The FDA has announced a sweeping ban on Red Dye No. 3, giving food companies three years to reformulate their products.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results